Skip to main content

Market Overview

CONMED Shares Initiated With Buy At Deutsche Bank


In a report published Monday, analysts at Deutsche Bank initiated coverage of CONMED Corporation (NASDAQ: CNMD) with a price target of $63. The company's execution capabilities are expected to improve following the appointment of its new CEO and several other experienced executives.

The underperformance of the company over the past few years incited shareholder activism, in response to which the company has made changes to its Board, while appointing a new Chairman, CEO and other executives. This, the analysts believe would lead to shareholder value being created with a greater strategic focus on commercial execution, "which in turn should improve the underlying fundamentals."

The company is expected to be able to execute on its goals during 2015, while bringing about an improvement in EBITDA growth and underlying sales. Acceleration opportunities exist for the company in the remainder of 2015.

"Looking longer term, we believe revenue growth can accelerate into the mid-single digits and with EBITDA margin expansion, we expect double digit EPS growth," the analysts added.

Latest Ratings for CNMD

May 2021BarclaysInitiates Coverage OnOverweight
Apr 2021Piper SandlerMaintainsOverweight
Jul 2020Piper SandlerMaintainsOverweight

View More Analyst Ratings for CNMD
View the Latest Analyst Ratings


Related Articles (CNMD)

View Comments and Join the Discussion!

Posted-In: Deutsche BankAnalyst Color Initiation Analyst Ratings

Latest Ratings

ATERRoth CapitalMaintains25.0
FMTXSVB LeerinkMaintains54.0
PLXSLoop CapitalMaintains105.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at